Sanofi Tries To Win Skeptics Over To Its Immunology Masterplan
Investors balked at Sanofi plans to raise R&D spending and eat into profits, so CEO Paul Hudson and new R&D chief Houman Ashrafian need to convince doubters that its immunology focused plan will pay off.
You may also be interested in...
Looking to treat patients with CSU uncontrolled by Xolair, Celldex’s KIT binder barzolvolimab shows strong disease activity reduction at 12 weeks in Phase II. Sanofi’s BTK inhibitor rilzabrutinib also showed efficacy in CSU.
Sarclisa has looked like an also-ran alongside J&J and Genmab’s Darzalex, but Sanofi’s drug could start to shine thanks to new first-line trial results
Hoping to become a leader in AI-assisted decision-making in biopharma, Sanofi has lifted the lid on some early progress in using the technology to make crucial portfolio investments.